KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Expenses (2016 - 2025)

Sarepta Therapeutics has reported Operating Expenses over the past 15 years, most recently at $854.5 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 72.03% year-over-year to $854.5 million; the TTM value through Dec 2025 reached $2.9 billion, up 72.1%, while the annual FY2025 figure was $2.9 billion, 72.1% up from the prior year.
  • Operating Expenses for Q4 2025 was $854.5 million at Sarepta Therapeutics, up from $502.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $1.0 billion in Q1 2025 and troughed at $223.9 million in Q3 2021.
  • A 5-year average of $436.2 million and a median of $375.4 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: dropped 20.33% in 2021 and later skyrocketed 176.11% in 2025.
  • Year by year, Operating Expenses stood at $307.3 million in 2021, then grew by 18.87% to $365.3 million in 2022, then grew by 1.89% to $372.2 million in 2023, then surged by 33.47% to $496.7 million in 2024, then skyrocketed by 72.03% to $854.5 million in 2025.
  • Business Quant data shows Operating Expenses for SRPT at $854.5 million in Q4 2025, $502.7 million in Q3 2025, and $495.5 million in Q2 2025.